

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
02 September 2021 (02.09.2021)



(10) International Publication Number
WO 2021/174165 A1

(51) International Patent Classification:

A61P 5/00 (2006.01) C07D 413/12 (2006.01)
A61P 9/00 (2006.01) C07D 417/12 (2006.01)
A61P 11/00 (2006.01) C07D 471/08 (2006.01)
A61P 31/00 (2006.01) C07D 487/10 (2006.01)
A61P 37/00 (2006.01) A61K 31/437 (2006.01)

(21) International Application Number:

PCT/US2021/020154

(22) International Filing Date:

28 February 2021 (28.02.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/983,541	28 February 2020 (28.02.2020)	US
63/007,333	08 April 2020 (08.04.2020)	US
63/040,484	17 June 2020 (17.06.2020)	US
63/072,790	31 August 2020 (31.08.2020)	US
63/126,492	16 December 2020 (16.12.2020)	US

(71) Applicant: **REMIX THERAPEUTICS INC.** [US/US];
One Kendall Square, Building 600, 4th Floor, Cambridge,
MA 02139 (US).

(72) Inventors: **REYNOLDS, Dominic**; One Kendall Square,
Building 600, 4th Floor, Cambridge, MA 02139 (US).
SEILER, Michael, Walker; One Kendall Square, Build-
ing 600, 4th Floor, Cambridge, MA 02139 (US). **AGRAW-
AL, Anant, A.**; One Kendall Square, Building 600, 4th
Floor, Cambridge, MA 02139 (US). **VAILLANCOURT,
Frederic**; One Kendall Square, Building 600, 4th Floor,
Cambridge, MA 02139 (US). **SMITH, Peter**; One Kendall
Square, Building 600, 4th Floor, Cambridge, MA 02139
(US).

(74) Agent: **LU, David** et al.; Lando & Anastasi, LLP, 60 State
Street, 23rd Floor, Boston, MA 02109 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,

CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) Title: HETEROCYCLIC AMIDES AND THEIR USE FOR MODULATING SPLICING



(57) Abstract: The present disclosure features compounds of formula (I-a) and related compositions that, inter alia, modulate nucleic acid splicing e.g., splicing of a pre-mRNA, as well as methods of use thereof.



WO 2021/174165 A1